HIGHLIGHTS
- who: Jiajin Wu from the Department of Urology, The First Affiliated Hospital of Nanjing Medical Province Hospital, No, Guangzhou Road, Nanjing, China have published the research: SPTBN1 abrogates renal clear cell carcinoma progression via glycolysis reprogramming in a GPT2-dependent manner, in the Journal: (JOURNAL)
- what: The research demonstrated that SPTBN1 is significantly down-regulated in ccRCC. The authors aimed to investigate the aberrant expression pattern of SPTBN1 in ccRCC and its tumor-suppressive role, as well as its interaction with downstream GPT2 to suppress tumor-required glycolysis.
- how: The results showed that . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.